ViewRay Reports Third Quarter 2020 Results
ViewRay, Inc. (Nasdaq: VRAY) reported a significant decline in total revenue for Q3 2020, generating $10.1 million, down from $20.9 million in Q3 2019. The company secured four new orders for MRIdian systems worth $23.4 million, noticeably less than the eight orders totaling $34.9 million received in the same quarter last year. Despite a total backlog increase to $238.9 million, ViewRay experienced a net loss of $28.1 million, compared to $20.8 million in Q3 2019. The company has robust cash reserves of $163.9 million and successfully amended its term loan to defer amortization payments until late 2022.
- Secured four new MRIdian orders totaling $23.4 million.
- Total backlog increased to $238.9 million.
- Cash and cash equivalents were strong at $163.9 million.
- Amended term loan to extend maturity to November 2025.
- Total revenue fell to $10.1 million from $20.9 million year-over-year.
- Net loss widened to $28.1 million compared to $20.8 million in Q3 2019.
- Total gross profit was a loss of $1.1 million, a decline from a profit of $0.6 million last year.
- Nine-month revenue decreased to $38.6 million from $71.3 million year-over-year.
CLEVELAND, Nov. 5, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2020.
Third Quarter 2020 Highlights:
- Total revenue of
$10.1 million , primarily from one revenue unit, compared to$20.9 million , primarily from three revenue units, in the third quarter of 2019. - Received four new orders for MRIdian systems totaling
$23.4 million , compared to eight new orders totaling$34.9 million in the third quarter of 2019. - Total backlog was
$238.9 million as of September 30, 2020, compared to$230.7 million as of September 30, 2019. - Cash and cash equivalents were
$163.9 million as of September 30, 2020. - Effective October 30, 2020, the Company amended its term loan with Silicon Valley Bank, deferring amortization until November 2022. Included in the amendment was an expansion of the facility from
$56 million to$58 million , the extension of maturity from December 2023 to November 2025, and other improvements to the interest rate and select covenants.
"We are pleased with our third quarter results in light of the economic backdrop," said Scott Drake, President and CEO. "MRIdian's clinical, strategic, and economic value propositions are resonating with customers. We received four orders in Q3, including an order from the Veterans Administration, which was a first for ViewRay. We look forward to partnering with the VA to provide the benefits of MRIdian to our nation's heroes. In addition, we continue to demonstrate fiscal discipline on operating expenses and working capital, and today announced the amendment of our term loan which extends maturity and defers amortization payments until late 2022."
Three Months Ended September 30, 2020 Financial Results:
Total revenue for the three months ended September 30, 2020 was
Total cost of revenue for the three months ended September 30, 2020 was
Total gross profit (loss) for the three months ended September 30, 2020 was
Total operating expenses for the three months ended September 30, 2020 were
Net loss for the three months ended September 30, 2020 was
ViewRay had total cash and cash equivalents of
Nine Months Ended September 30, 2020 Financial Results:
Total revenue for the nine months ended September 30, 2020 was
Total cost of revenue for the nine months ended September 30, 2020 was
Total gross profit (loss) for the nine months ended September 30, 2020 was
Total operating expenses for the nine months ended September 30, 2020 were
Net loss for the nine months ended September 30, 2020 was
Conference Call and Webcast
The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 9819479. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.
After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until November 12, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 9819479.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's preliminary third quarter results and anticipated future operating and financial performance, and ViewRay's conference call to discuss its third quarter 2020 results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
VIEWRAY, INC. | ||||||||||||||||
Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
(Unaudited) | ||||||||||||||||
(In thousands, except share and per share data) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Revenue: | ||||||||||||||||
Product | $ | 6,210 | $ | 18,696 | $ | 28,295 | $ | 65,475 | ||||||||
Service | 3,758 | 2,048 | 9,909 | 5,482 | ||||||||||||
Distribution rights | 118 | 118 | 356 | 356 | ||||||||||||
Total revenue | 10,086 | 20,862 | 38,560 | 71,313 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Product | 8,550 | 18,521 | 34,393 | 63,368 | ||||||||||||
Service | 2,600 | 1,767 | 8,380 | 9,489 | ||||||||||||
Total cost of revenue | 11,150 | 20,288 | 42,773 | 72,857 | ||||||||||||
Gross margin | (1,064) | 574 | (4,213) | (1,544) | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 5,245 | 5,641 | 17,793 | 17,135 | ||||||||||||
Selling and marketing | 2,669 | 7,297 | 11,585 | 19,845 | ||||||||||||
General and administrative | 16,031 | 19,381 | 47,046 | 49,888 | ||||||||||||
Total operating expenses | 23,945 | 32,319 | 76,424 | 86,868 | ||||||||||||
Loss from operations | (25,009) | (31,745) | (80,637) | (88,412) | ||||||||||||
Interest income | 5 | 484 | 787 | 1,391 | ||||||||||||
Interest expense | (1,074) | (1,069) | (3,183) | (2,902) | ||||||||||||
Other (expense) income, net | (2,047) | 11,499 | 1,224 | 4,933 | ||||||||||||
Loss before provision for income taxes | $ | (28,125) | $ | (20,831) | $ | (81,809) | $ | (84,990) | ||||||||
Provision for income taxes | — | — | — | — | ||||||||||||
Net loss and comprehensive loss | $ | (28,125) | $ | (20,831) | $ | (81,809) | $ | (84,990) | ||||||||
Net loss per share, basic and diluted | $ | (0.19) | $ | (0.21) | $ | (0.55) | $ | (0.87) | ||||||||
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted | 148,042,972 | 99,039,789 | 147,683,344 | 97,763,964 | ||||||||||||
VIEWRAY, INC. | ||||||||
Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
(In thousands, except share and per share data) | ||||||||
September 30, 2020 | December 31, 2019 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 163,881 | $ | 226,783 | ||||
Accounts receivable | 26,548 | 16,817 | ||||||
Inventory | 46,456 | 55,031 | ||||||
Deposits on purchased inventory | 4,254 | 6,457 | ||||||
Deferred cost of revenue | 8,705 | 3,466 | ||||||
Prepaid expenses and other current assets | 4,659 | 3,310 | ||||||
Total current assets | 254,503 | 311,864 | ||||||
Property and equipment, net | 22,533 | 23,399 | ||||||
Restricted cash | 1,460 | 1,404 | ||||||
Intangible assets, net | 51 | 55 | ||||||
Right-of-use assets | 10,055 | 11,720 | ||||||
Other assets | 1,485 | 1,577 | ||||||
TOTAL ASSETS | $ | 290,087 | $ | 350,019 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 7,607 | $ | 13,739 | ||||
Accrued liabilities | 17,966 | 21,390 | ||||||
Customer deposits | 16,080 | 9,662 | ||||||
Operating lease liability, current | 2,251 | 2,264 | ||||||
Current portion of long-term debt | 15,556 | 1,556 | ||||||
Deferred revenue, current | 21,838 | 10,457 | ||||||
Total current liabilities | 81,298 | 59,068 | ||||||
Deferred revenue, net of current portion | 2,884 | 3,553 | ||||||
Long-term debt | 40,134 | 53,995 | ||||||
Warrant liabilities | 4,092 | 5,373 | ||||||
Operating lease liability, noncurrent | 8,816 | 10,479 | ||||||
Other long-term liabilities | 1,827 | 1,377 | ||||||
TOTAL LIABILITIES | 139,051 | 133,845 | ||||||
Commitments and contingencies (Note 6) | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, par value of | — | — | ||||||
Common stock, par value of | 1,469 | 1,462 | ||||||
Additional paid-in capital | 750,552 | 733,888 | ||||||
Accumulated deficit | (600,985) | (519,176) | ||||||
TOTAL STOCKHOLDERS' EQUITY | 151,036 | 216,174 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 290,087 | $ | 350,019 | ||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/viewray-reports-third-quarter-2020-results-301167379.html
SOURCE ViewRay Incorporated
FAQ
What were ViewRay's total revenues for Q3 2020?
How did ViewRay's revenue in Q3 2020 compare to Q3 2019?
What is ViewRay's net loss for Q3 2020?
How much cash does ViewRay have as of September 30, 2020?
What were the main highlights for ViewRay in Q3 2020?
